Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: May 1, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
28
2023 to 2026
Breakthrough
1
Accelerated
0
Priority review
3
Orphan
3
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 1 | 6 |
| 2024 | 1 | 7 |
| 2025 | 2 | 7 |
| 2026 | 3 | 1 |
28 approvals
Newest first. Hover a badge for what it means.
- Jakafi Xr (Ruxolitinib Phosphate) · Incyte CorpMay 1, 2026
- Icotyde (Icotrokinra Hydrochloride) · Janssen BiotechMar 17, 2026
To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy
- Adquey (Difamilast) · Acrotech BiopharmaFeb 12, 2026
To treat mild to moderate atopic dermatitis
- Avtozma (Tocilizumab-Anoh) · Celltrion INCJan 21, 2026Original approval · BLA 761498Approval letter
- Rhapsido (Remibrutinib) · NovartisSep 30, 2025
To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatment
- Anzupgo (Delgocitinib) · Leo Pharma AsJul 23, 2025
To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response
- Starjemza (Ustekinumab-Hmny) · Bio-Thera Solutions LTDMay 22, 2025Original approval · BLA 761419Approval letter
- Steqeyma (Ustekinumab-Stba) · Celltrion, Inc.Apr 30, 2025Original approval · BLA 761338Approval letter
- Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDApr 30, 2025Original approval · BLA 761373Approval letter
- Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDApr 30, 2025Original approval · BLA 761425Approval letter
- Otulfi (Ustekinumab-Aauz) · Fresenius Kabi USAApr 30, 2025Original approval · BLA 761379Approval letter
- Tyenne (Tocilizumab-Aazg) · Fresenius Kabi USAMar 14, 2025Original approval · BLA 761449Approval letter
- Avtozma (Tocilizumab-Anoh) · Celltrion INCJan 24, 2025Original approval · BLA 761420Approval letter
- Steqeyma (Ustekinumab-Stba) · Celltrion, Inc.Dec 17, 2024Original approval · BLA 761338Approval letter
- Otulfi (Ustekinumab-Aauz) · Fresenius Kabi USASep 27, 2024Original approval · BLA 761379Approval letter
- Ebglyss (Lebrikizumab-Lbkz) · Eli Lilly and COSep 13, 2024
To treat moderate-to-severe atopic dermatitis
- Nemluvio (Nemolizumab-Ilto) · Galderma Labs LpAug 12, 2024
To treat prurigo nodularis
- Leqselvi (Deuruxolitinib Phosphate) · Sun Pharm Inds INCJul 25, 2024
To treat severe alopecia areata
- Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDJun 28, 2024Original approval · BLA 761373Approval letter
- Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTDJun 28, 2024Original approval · BLA 761425Approval letter
- Tyenne (Tocilizumab-Aazg) · Fresenius Kabi USAMar 5, 2024
- Wezlana (Ustekinumab-Auub) · Amgen INCOct 31, 2023Original approval · BLA 761285Approval letter
- Wezlana (Ustekinumab-Auub) · Amgen INCOct 31, 2023Original approval · BLA 761331Approval letter
- Omvoh (Mirikizumab-Mrkz) · Eli Lilly and COOct 26, 2023
To treat ulcerative colitis
- Bimzelx (Bimekizumab-Bkzx) · Ucb INCOct 17, 2023
To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- Velsipity (Etrasimod Arginine) · PfizerOct 12, 2023
To treat moderately to severely active ulcerative colitis in adults
- Cosentyx (Secukinumab) · Novartis Pharms CorpOct 6, 2023Original approval · BLA 761349Approval letter
- Tofidence (Tocilizumab-Bavi) · Biogen MaSep 29, 2023Original approval · BLA 761354Approval letter
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.